S&P 500   4,953.87 (-0.43%)
DOW   38,437.05 (-0.33%)
QQQ   423.66 (-0.86%)
AAPL   181.16 (-0.22%)
MSFT   399.39 (-0.84%)
META   467.46 (-0.80%)
GOOGL   142.34 (+0.86%)
AMZN   168.33 (+0.75%)
TSLA   194.07 (+0.16%)
NVDA   674.38 (-2.90%)
NIO   6.08 (+2.01%)
AMD   163.82 (-1.13%)
BABA   75.60 (+3.36%)
T   16.92 (+0.06%)
F   12.11 (-1.14%)
MU   80.56 (-0.19%)
CGC   3.40 (-3.95%)
GE   148.28 (-0.23%)
DIS   107.70 (-1.59%)
AMC   4.54 (-2.58%)
PFE   27.45 (-0.51%)
PYPL   57.52 (-1.89%)
XOM   104.84 (+2.03%)
S&P 500   4,953.87 (-0.43%)
DOW   38,437.05 (-0.33%)
QQQ   423.66 (-0.86%)
AAPL   181.16 (-0.22%)
MSFT   399.39 (-0.84%)
META   467.46 (-0.80%)
GOOGL   142.34 (+0.86%)
AMZN   168.33 (+0.75%)
TSLA   194.07 (+0.16%)
NVDA   674.38 (-2.90%)
NIO   6.08 (+2.01%)
AMD   163.82 (-1.13%)
BABA   75.60 (+3.36%)
T   16.92 (+0.06%)
F   12.11 (-1.14%)
MU   80.56 (-0.19%)
CGC   3.40 (-3.95%)
GE   148.28 (-0.23%)
DIS   107.70 (-1.59%)
AMC   4.54 (-2.58%)
PFE   27.45 (-0.51%)
PYPL   57.52 (-1.89%)
XOM   104.84 (+2.03%)
S&P 500   4,953.87 (-0.43%)
DOW   38,437.05 (-0.33%)
QQQ   423.66 (-0.86%)
AAPL   181.16 (-0.22%)
MSFT   399.39 (-0.84%)
META   467.46 (-0.80%)
GOOGL   142.34 (+0.86%)
AMZN   168.33 (+0.75%)
TSLA   194.07 (+0.16%)
NVDA   674.38 (-2.90%)
NIO   6.08 (+2.01%)
AMD   163.82 (-1.13%)
BABA   75.60 (+3.36%)
T   16.92 (+0.06%)
F   12.11 (-1.14%)
MU   80.56 (-0.19%)
CGC   3.40 (-3.95%)
GE   148.28 (-0.23%)
DIS   107.70 (-1.59%)
AMC   4.54 (-2.58%)
PFE   27.45 (-0.51%)
PYPL   57.52 (-1.89%)
XOM   104.84 (+2.03%)
S&P 500   4,953.87 (-0.43%)
DOW   38,437.05 (-0.33%)
QQQ   423.66 (-0.86%)
AAPL   181.16 (-0.22%)
MSFT   399.39 (-0.84%)
META   467.46 (-0.80%)
GOOGL   142.34 (+0.86%)
AMZN   168.33 (+0.75%)
TSLA   194.07 (+0.16%)
NVDA   674.38 (-2.90%)
NIO   6.08 (+2.01%)
AMD   163.82 (-1.13%)
BABA   75.60 (+3.36%)
T   16.92 (+0.06%)
F   12.11 (-1.14%)
MU   80.56 (-0.19%)
CGC   3.40 (-3.95%)
GE   148.28 (-0.23%)
DIS   107.70 (-1.59%)
AMC   4.54 (-2.58%)
PFE   27.45 (-0.51%)
PYPL   57.52 (-1.89%)
XOM   104.84 (+2.03%)
NASDAQ:RCKT

Rocket Pharmaceuticals (RCKT) Stock Price, News & Analysis

$28.38
-0.26 (-0.91%)
(As of 02:16 PM ET)
Today's Range
$28.17
$28.87
50-Day Range
$26.16
$31.94
52-Week Range
$14.89
$32.53
Volume
191,237 shs
Average Volume
681,138 shs
Market Capitalization
$2.56 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$54.80

Rocket Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
92.6% Upside
$54.80 Price Target
Short Interest
Bearish
9.37% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.81
Upright™ Environmental Score
News Sentiment
0.03mentions of Rocket Pharmaceuticals in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$17,354 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.02) to ($3.04) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.92 out of 5 stars

Medical Sector

208th out of 932 stocks

Pharmaceutical Preparations Industry

89th out of 431 stocks


RCKT stock logo

About Rocket Pharmaceuticals Stock (NASDAQ:RCKT)

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. The company is headquartered in Cranbury, New Jersey.

RCKT Stock Price History

RCKT Stock News Headlines

An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
FDA Extends Review of Rocket Pharma's Proposed Kresladi
See More Headlines
Receive RCKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/06/2023
Today
2/21/2024
Next Earnings (Estimated)
2/26/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RCKT
Employees
240
Year Founded
2018

Price Target and Rating

Average Stock Price Target
$54.80
High Stock Price Target
$65.00
Low Stock Price Target
$47.00
Potential Upside/Downside
+91.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-221,860,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.47 per share

Miscellaneous

Free Float
62,120,000
Market Cap
$2.58 billion
Optionable
Optionable
Beta
1.11

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Gaurav D. Shah M.D. (Age 49)
    CEO & Director
    Comp: $1.05M
  • Ms. Kinnari Patel M.B.A. (Age 45)
    Pharm.D., President & COO
    Comp: $849.93k
  • Mr. John C. Militello CPAMr. John C. Militello CPA (Age 51)
    VP, Senior Controller, Treasurer, Principal Accounting Officer & Interim Principal Financial Officer
    Comp: $501.42k
  • Mr. Mayo Pujols (Age 55)
    Chief Technical Officer & Executive VP
    Comp: $649.71k
  • Mr. Raj Prabhakar M.B.A. (Age 50)
    Senior VP & Chief Business Officer
    Comp: $619.13k
  • Mr. Martin Louis Wilson J.D. (Age 48)
    General Counsel, Chief Compliance Officer & Senior VP
    Comp: $149.95k
  • Kevin Giordano
    Director of Corporate Communications
  • Ms. Isabel Carmona J.D.
    Senior VP & Chief Human Resources Officer
  • Mr. Jonathan Schwartz M.D. (Age 59)
    Chief Gene Therapy Officer & Senior VP of Clinical Development
    Comp: $557.79k
  • Dr. Gayatri R. Rao J.D.
    M.D., Chief Development Officer of LVV & Senior VP














RCKT Stock Analysis - Frequently Asked Questions

Should I buy or sell Rocket Pharmaceuticals stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RCKT shares.
View RCKT analyst ratings
or view top-rated stocks.

What is Rocket Pharmaceuticals' stock price target for 2024?

7 analysts have issued 12 month price objectives for Rocket Pharmaceuticals' stock. Their RCKT share price targets range from $47.00 to $65.00. On average, they anticipate the company's share price to reach $54.80 in the next year. This suggests a possible upside of 92.6% from the stock's current price.
View analysts price targets for RCKT
or view top-rated stocks among Wall Street analysts.

How have RCKT shares performed in 2024?

Rocket Pharmaceuticals' stock was trading at $29.97 at the beginning of 2024. Since then, RCKT shares have decreased by 5.1% and is now trading at $28.45.
View the best growth stocks for 2024 here
.

When is Rocket Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our RCKT earnings forecast
.

How were Rocket Pharmaceuticals' earnings last quarter?

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) posted its quarterly earnings results on Monday, November, 6th. The biotechnology company reported ($0.75) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.81) by $0.06. During the same quarter in the prior year, the company earned ($0.87) EPS.

What ETFs hold Rocket Pharmaceuticals' stock?
What other stocks do shareholders of Rocket Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Energy Transfer (ET), Micron Technology (MU), VBI Vaccines (VBIV), Vaxart (VXRT) and Alibaba Group (BABA).

Who are Rocket Pharmaceuticals' major shareholders?

Rocket Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (6.04%), Westfield Capital Management Co. LP (4.37%), Price T Rowe Associates Inc. MD (2.92%), Price T Rowe Associates Inc. MD (2.92%), Avidity Partners Management LP (1.91%) and Frazier Life Sciences Management L.P. (1.69%). Insiders that own company stock include Gaurav Shah, Gotham Makker, John Militello, Jonathan David Schwartz, Kinnari Patel and Rtw Investments, Lp.
View institutional ownership trends
.

How do I buy shares of Rocket Pharmaceuticals?

Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RCKT) was last updated on 2/21/2024 by MarketBeat.com Staff